All News
#ACR22 Abstr#0004 Macrophage Activation Syndrome is associated with Systemic JIA #arthritis but how do they link up? Mice studies show mTORC1 is a key driver. Studies needed to assess mTORC1-inhibitor e.g. rapamycin, sirolimus etc. for SJIA-related MAS @RheumNow https://t.co/sH9seK1n8u
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Why are #sJIA pts prone to #MAS?
Potential new treatment target mTORC1?
mTORC1 gene signature in monocytes
Mice models and human translational studies with evidence
#ACRBest #ACR22 @rheumnow abst#0004 #stillsdisease #autoinflammatorydisease https://t.co/Q2ehfyWMKG
Bella Mehta bella_mehta ( View Tweet)
Safety data from 9 phase 3 UPA trials (RA, PsA & AS). In 11,271 pt-yrs exposure, no increased signal for cancer (excluding NMSC) cf. ADA/MTX. NMSC was higher however.
What data (if any) would reassure people in this space?
@RheumNow ABST0292 #ACR22
https://t.co/tS5r66loqP
Julian Segan JulianSegan ( View Tweet)
MIRROR RCT: Pegloticase + MTX 60% response rate vs. 30% Pegloticase + PBO in uncontrolled gout patients. 1/2 patients w/ resolution of >= 1tophus in MTX gpe vs. < 1/3 in PBO. Safety profile comparable between groups.
https://t.co/oJ6kYw94L3 Abst#0001 #ACR22 @Rheumnow https://t.co/Hmeym3Cy7n
Aurelie Najm AurelieRheumo ( View Tweet)
Beautiful translational work looking at mTORC1 driving systemic JIA to MAS - a deadly escalation.
An already accessible target:
Rapamycin in sJIA a serious proposition!
ABST0004 @BostonChildrens #ACR22 @RheumNow https://t.co/fW3C5ludjc
David Liew drdavidliew ( View Tweet)
RECITAL trial: First line RTX vs. CYC in ILD 🫁 asso w/ SSc, mixed CTD or Myositis.
Primart endpoint FVC 24 wks improved in both mCTD and Myositis associated ILD but only stabilized in SSc-ILD. RTX improved skin thickness 24 wks. https://t.co/MQcqds0jYA
Abst#0003 #ACR22 @Rheumnow https://t.co/pK48716nIg
Aurelie Najm AurelieRheumo ( View Tweet)
#acrbest #abst0004 #acr22 @rheumnow 🐁 model of excessive mTORC1 activation in JIA confirms unrestricted activation of mTORC1 sufficient to trigger sJIA-like syndrome including MAS w/hemophagocytosis. rapamycin prevents MAS & ⬇️ arthritis severity & bone erosion in Il1rn-/- mice https://t.co/2HSXOJ6tX8
Olga Petryna DrPetryna ( View Tweet)
If rheumatologists were distributed equitably in the US, the Navajo nation should have 19 rheumatologists.
They have just one.
Very exciting scalable program to empower primary care. Enormously powerful, both there and elsewhere
ABST0005 @jrmandal @JYazdanyMD #ACR22 @RheumNow https://t.co/mOtgLomZLM
David Liew drdavidliew ( View Tweet)
Only small changes in lipid profile and no change in arterial inflammation (measured by FDG-PET) in both TNFi/MTX and triple therapy groups over a 24 week period in the TARGET trial.
What do you think could account for this? Follow-up period too short?
@RheumNow ABST0254 #ACR22 https://t.co/JMJ7WgXyJX
Julian Segan JulianSegan ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view.
#plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY
TheDaoIndex KDAO2011 ( View Tweet)
Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high risk pts! Can even consider PET/CT, CT, pelvic US, initially. Question is... will insurances approve all of these tests?
Abs#0002 @RheumNow #ACR22 https://t.co/uvr4jGVTFP
Robert B Chao, MD doctorRBC ( View Tweet)
Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR22 @rheumnow #myositis https://t.co/vJ82rEX2wk
TheDaoIndex KDAO2011 ( View Tweet)
Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO
Tagging off BLISS-LN, pooled analysis w/marginal but real benefit to adding BEL in pts with SLE
I offer this to all pts w/SLE LN on MMF, but I do not push it
#ACRbest #ACR22 @RheumNow #0352 https://t.co/QYGgB3ue36
Mike Putman EBRheum ( View Tweet)
Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plenary #ACR22 @rheumnow #myositis #ExpertOpinionNotData https://t.co/cL6zrMnzT3
TheDaoIndex KDAO2011 ( View Tweet)
Cancer screening in myositis:
the path has always been unclear and inconsistent
Workable consensus recommendations @Dr_Alex_Oldroyd
risk stratification but still extensive investigation burden for most
now need to look at effectiveness including cost
ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K
David Liew drdavidliew ( View Tweet)
#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO
TheDaoIndex KDAO2011 ( View Tweet)
Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22
@rheumnow #myositis https://t.co/pPLcsFLtG9
TheDaoIndex KDAO2011 ( View Tweet)
Consensus for CA screening in IIM Presented: Risk factors to consider screening
#Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS
TheDaoIndex KDAO2011 ( View Tweet)